This is a preprint.
Symptomatic malaria enhances protection from reinfection with homologous Plasmodium falciparum parasites
- PMID: 36711685
- PMCID: PMC9882554
- DOI: 10.1101/2023.01.04.23284198
Symptomatic malaria enhances protection from reinfection with homologous Plasmodium falciparum parasites
Update in
-
Symptomatic malaria enhances protection from reinfection with homologous Plasmodium falciparum parasites.PLoS Pathog. 2023 Jun 12;19(6):e1011442. doi: 10.1371/journal.ppat.1011442. eCollection 2023 Jun. PLoS Pathog. 2023. PMID: 37307293 Free PMC article.
Abstract
A signature remains elusive of naturally-acquired immunity against Plasmodium falciparum . We identified P. falciparum in a 14-month cohort of 239 people in Kenya, genotyped at immunogenic parasite targets expressed in the pre-erythrocytic (circumsporozoite protein, CSP) and blood (apical membrane antigen 1, AMA-1) stages, and classified into epitope type based on variants in the DV10, Th2R, and Th3R epitopes in CSP and the c1L region of AMA-1. Compared to asymptomatic index infections, symptomatic malaria was associated with a reduced reinfection by parasites bearing homologous CSP-Th2R (adjusted hazard ratio [aHR]:0.63; 95% CI:0.45-0.89; p=0.008) CSP-Th3R (aHR:0.71; 95% CI:0.52-0.97; p=0.033), and AMA-1 c1L (aHR:0.63; 95% CI:0.43-0.94; p=0.022) epitope types. The association of symptomatic malaria with reduced risk of homologous reinfection was strongest for rare epitope types. Symptomatic malaria more effectively promotes functional immune responses. The phenotype represents a legible molecular epidemiologic signature of naturally-acquired immunity by which to identify new antigen targets.
Conflict of interest statement
CONFLICT OF INTEREST
The authors have no conflicts of interest to declare.
Figures





References
-
- WHO. World Malaria Report 2018, <https://www.who.int/malaria/publications/world-malaria-report-2018/en/> (2018).
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources